NO20072115L - Farmasoytiske forbindelser - Google Patents
Farmasoytiske forbindelserInfo
- Publication number
- NO20072115L NO20072115L NO20072115A NO20072115A NO20072115L NO 20072115 L NO20072115 L NO 20072115L NO 20072115 A NO20072115 A NO 20072115A NO 20072115 A NO20072115 A NO 20072115A NO 20072115 L NO20072115 L NO 20072115L
- Authority
- NO
- Norway
- Prior art keywords
- substituted
- group
- unsubstituted
- membered saturated
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0423653.5A GB0423653D0 (en) | 2004-10-25 | 2004-10-25 | Pharmaceutical compounds |
PCT/GB2005/004137 WO2006046035A1 (en) | 2004-10-25 | 2005-10-25 | Pharmaceutical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072115L true NO20072115L (no) | 2007-07-24 |
Family
ID=33485146
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072116A NO20072116L (no) | 2004-10-25 | 2007-04-24 | Farmasoytiske forbindelser |
NO20072115A NO20072115L (no) | 2004-10-25 | 2007-04-24 | Farmasoytiske forbindelser |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072116A NO20072116L (no) | 2004-10-25 | 2007-04-24 | Farmasoytiske forbindelser |
Country Status (17)
Country | Link |
---|---|
US (8) | US7776856B2 (es) |
EP (3) | EP1812445B1 (es) |
JP (3) | JP5048504B2 (es) |
KR (3) | KR101466529B1 (es) |
CN (2) | CN101087795B (es) |
AU (2) | AU2005298408B2 (es) |
BR (2) | BRPI0517461A (es) |
CA (2) | CA2585089C (es) |
ES (3) | ES2554689T3 (es) |
GB (1) | GB0423653D0 (es) |
IL (2) | IL182614A (es) |
MX (2) | MX2007004867A (es) |
NO (2) | NO20072116L (es) |
NZ (2) | NZ554585A (es) |
RU (2) | RU2422449C2 (es) |
WO (3) | WO2006046031A1 (es) |
ZA (2) | ZA200703312B (es) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69636466T2 (de) * | 1996-09-04 | 2007-08-09 | Intertrust Technologies Corp., Sunnyvale | Treuhand infrastruktur unterstützungssysteme, verfahren und techniken zum sicheren elektronischen handel, elektronische transaktionen, steuerung und automatisierung von handelsverfahren, verteilte datenverarbeitung und verwalten von rechten |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
ES2347187T3 (es) | 2006-04-26 | 2010-10-26 | F. Hoffmann-La Roche Ag | Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k. |
US8252792B2 (en) * | 2006-04-26 | 2012-08-28 | F. Hoffman-La Roche Ag | Pyrimidine derivatives as PI3K inhibitors |
SI2024372T1 (sl) * | 2006-04-26 | 2010-10-29 | Hoffmann La Roche | Tieno(3,2-d)pirimidinski derivat, uporaben kot inhibitor PI3K |
TWI498332B (zh) | 2006-04-26 | 2015-09-01 | Hoffmann La Roche | 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物 |
MX2008013583A (es) * | 2006-04-26 | 2008-10-31 | Genentech Inc | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. |
GB0608820D0 (en) * | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
GB0611152D0 (en) * | 2006-06-06 | 2006-07-19 | Ucb Sa | Therapeutic agents |
EP2043654A2 (en) | 2006-06-12 | 2009-04-08 | Vertex Pharmaceuticals, Inc. | Thienopyrimidines useful as modulators of ion channels |
GB0612630D0 (en) | 2006-06-26 | 2006-08-02 | Novartis Ag | Organic compounds |
EP2441768A1 (en) * | 2006-11-13 | 2012-04-18 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
EP2114950B1 (en) * | 2006-12-07 | 2016-03-09 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
BRPI0717923A2 (pt) | 2006-12-07 | 2013-10-22 | Genentech In | '' composto, composição farmacêutica, método para tratar um câncer, processo para a produção de uma composição farmacêutica, usos, métodos para inibir ou modular a atividade da lipídeo quinase e kit ' ' |
CA2692050A1 (en) * | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
WO2008152394A1 (en) * | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
US8247397B2 (en) * | 2007-09-12 | 2012-08-21 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
WO2009042607A1 (en) | 2007-09-24 | 2009-04-02 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
EP2214675B1 (en) * | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
CA2703138A1 (en) * | 2007-10-26 | 2009-04-30 | F. Hoffmann-La Roche Ag | Purine derivatives useful as pi3 kinase inhibitors |
PE20131210A1 (es) | 2007-12-19 | 2013-10-31 | Genentech Inc | Derivados de 5-anilinoimidazopiridina como inhibidores de mek |
JP5520831B2 (ja) | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
AU2008340247B2 (en) | 2007-12-21 | 2012-11-15 | Genentech, Inc. | Azaindolizines and methods of use |
US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
DK2644194T3 (en) | 2008-03-18 | 2017-07-03 | Genentech Inc | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
RS58724B1 (sr) * | 2008-05-23 | 2019-06-28 | Wyeth Llc | Jedinjenja triazina kao inhibitori pi3 kinaze i mtor |
EP2279188B1 (en) | 2008-05-30 | 2015-01-28 | Genentech, Inc. | Purine pi3k inhibitor compounds and methods of use |
ES2474147T3 (es) | 2008-05-30 | 2014-07-08 | Amgen, Inc | Inhibidores de PI3 cinasa |
TW201018681A (en) * | 2008-07-31 | 2010-05-16 | Genentech Inc | Pyrimidine compounds, compositions and methods of use |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
KR20140094590A (ko) | 2009-01-08 | 2014-07-30 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나제 억제제 |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
CA2750935A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
CN102365021B (zh) | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
KR101781654B1 (ko) | 2009-03-12 | 2017-09-25 | 제넨테크, 인크. | 조혈 악성종양의 치료를 위한 포스포이노시티드 3-키나제 억제제 화합물 및 화학요법제의 조합물 |
CA2755285C (en) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
EP2411398B1 (en) | 2009-03-24 | 2014-12-17 | Sumitomo Chemical Company, Limited | Method for manufacturing a boronic acid ester compound |
CN102448958B (zh) | 2009-03-27 | 2015-10-21 | 维特Dc公司 | 嘧啶基和1,3,5-三嗪基苯并咪唑磺酰胺和其在癌症治疗中的用途 |
WO2010119264A1 (en) | 2009-04-16 | 2010-10-21 | Centro Nacional De Investigaciones Oncólogicas (Cnio) | Imidazopyrazines for use as kinase inhibitors |
EP2432321B1 (en) | 2009-05-20 | 2017-06-14 | Glaxosmithkline LLC | Thiazolopyrimidinone derivatives as pi3 kinase inhibitors |
US8158625B2 (en) * | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
MX2011012520A (es) * | 2009-05-27 | 2011-12-12 | Hoffmann La Roche | Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos. |
EP2445346A4 (en) * | 2009-06-24 | 2012-12-05 | Genentech Inc | OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE |
MX2012000178A (es) * | 2009-07-02 | 2012-02-28 | Novartis Ag | 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k. |
BR112012001325A2 (pt) | 2009-07-21 | 2017-05-02 | Gilead Calistoga Llc | tratamento de distúrbios do fígado com inibidaores de pi3k |
BR112012003955A2 (pt) | 2009-08-20 | 2017-09-26 | Karus Therapeutics Ltd | compostos heterocíclicos tricíclicos como inibidores da fosfoinositídeos 3-quinase |
SG10201405568UA (en) | 2009-09-08 | 2014-11-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
CN104987345A (zh) | 2009-09-28 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 苯并氧杂*pi3k抑制剂化合物和使用方法 |
TWI428336B (zh) * | 2009-10-12 | 2014-03-01 | Hoffmann La Roche | Pi3k抑制劑及mek抑制劑之組合 |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
CA3022722A1 (en) | 2009-11-05 | 2011-05-12 | Rhizen Pharmaceuticals S.A. | Pi3k protein kinase modulators |
CA2778686C (en) * | 2009-11-12 | 2015-07-21 | F. Hoffmann-La Roche Ag | N-9-substituted purine compounds, compositions and methods of use |
BR112012011147A2 (pt) * | 2009-11-12 | 2021-09-08 | F.Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto. |
KR20120111739A (ko) | 2009-12-31 | 2012-10-10 | 센트로 내셔널 드 인베스티가시오네스 온콜로지카스 (씨엔아이오) | 키나제 억제제로서의 사용을 위한 삼환식 화합물 |
CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
WO2011097333A1 (en) | 2010-02-03 | 2011-08-11 | Signal Pharmaceuticals, Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
US9173961B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
US8440651B2 (en) | 2010-02-22 | 2013-05-14 | F. Hoffmann-La Roche Ag | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use |
MX2012011887A (es) | 2010-04-16 | 2012-11-30 | Genentech Inc | Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt. |
US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
ES2536780T3 (es) * | 2010-07-14 | 2015-05-28 | F. Hoffmann-La Roche Ag | Compuestos de purina selectivos para I3 p110 delta, y métodos de uso |
JP2013536193A (ja) | 2010-08-11 | 2013-09-19 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリール類およびその使用 |
WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
JP2013533318A (ja) | 2010-08-11 | 2013-08-22 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリールおよびその使用 |
AR083450A1 (es) | 2010-10-13 | 2013-02-27 | Millennium Pharm Inc | Heteroarilos y sus usos en el tratamiento de enfermedades proliferativas, inflamatorias o cardiovasculares |
EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
NZ609448A (en) | 2010-12-16 | 2015-07-31 | Hoffmann La Roche | Tricyclic pi3k inhibitor compounds and methods of use |
WO2012088254A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
RU2013138835A (ru) | 2011-02-09 | 2015-03-20 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения в качестве ингибиторов pi3 киназы |
EP2675479B1 (en) | 2011-02-15 | 2016-01-13 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
KR20140032383A (ko) | 2011-03-21 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법 |
LT3111938T (lt) | 2011-04-01 | 2019-06-25 | Curis, Inc. | Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi |
JP6118314B2 (ja) | 2011-05-04 | 2017-04-19 | ライゼン・ファーマシューティカルズ・エスアー | タンパク質キナーゼのモジュレーターとしての新規化合物 |
MX2014001246A (es) | 2011-08-03 | 2014-06-11 | Signal Pharm Llc | Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1. |
EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
CN103957902A (zh) | 2011-10-13 | 2014-07-30 | 基因泰克公司 | 药理学诱导的胃酸过少的治疗 |
AU2012354094C1 (en) | 2011-12-15 | 2015-10-15 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
KR20160027218A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
KR101689946B1 (ko) | 2012-06-08 | 2016-12-26 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
EP2870157B1 (en) | 2012-07-04 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Selective pi3k delta inhibitors |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
WO2014056955A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | Process for making thienopyrimidine compounds |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
IN2015DN03235A (es) | 2012-11-07 | 2015-10-02 | Karus Therapeutics Ltd | |
EP2928488A1 (en) * | 2012-12-07 | 2015-10-14 | The General Hospital Corporation | Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
KR102182488B1 (ko) | 2013-02-25 | 2020-11-24 | 제넨테크, 인크. | 약물 내성 akt 돌연변이체의 검출 및 치료를 위한 방법 및 조성물 |
WO2014134486A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
KR20160002792A (ko) | 2013-04-17 | 2016-01-08 | 시그날 파마소티칼 엘엘씨 | 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법 |
CN105377299B (zh) | 2013-04-17 | 2018-06-12 | 西格诺药品有限公司 | 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法 |
US9359364B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one |
EP2986322A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
EA030808B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ |
BR112015026247B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit |
TWI656875B (zh) | 2013-04-17 | 2019-04-21 | 美商標誌製藥公司 | 藉二氫吡并吡治療癌症 |
WO2014177915A1 (en) | 2013-05-01 | 2014-11-06 | Piramal Enterprises Limited | Cancer combination therapy using imidazo[4,5-c]quinoline derivatives |
RS57816B1 (sr) | 2013-05-10 | 2018-12-31 | Karus Therapeutics Ltd | Inhibitori histon deacetilaze |
DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
NZ629486A (en) | 2013-05-29 | 2017-11-24 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
KR101648141B1 (ko) | 2013-06-11 | 2016-08-12 | 제일모직 주식회사 | 화합물, 이를 포함하는 유기 광전자 소자 및 상기 유기 광전자 소자를 포함하는 표시장치 |
CN104418858B (zh) | 2013-08-30 | 2018-12-11 | 浙江医药股份有限公司新昌制药厂 | 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用 |
JP6441910B2 (ja) * | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
SG11201607334YA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
RU2016148441A (ru) | 2014-05-21 | 2018-06-22 | Ф. Хоффманн-Ля Рош Аг | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом |
GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
KR20180012324A (ko) | 2015-06-29 | 2018-02-05 | 에프. 호프만-라 로슈 아게 | 타셀리십을 사용하는 치료 방법 |
WO2017001658A1 (en) | 2015-07-02 | 2017-01-05 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
UA121678C2 (uk) | 2015-07-02 | 2020-07-10 | Ф. Хоффманн-Ля Рош Аг | Сполука бензоксазепіноксазолідинонів та способи застосування |
LT3325623T (lt) | 2015-07-23 | 2019-10-25 | Inst Curie | Dbait molekulės ir parp inhibitorių derinio panaudojimas vėžiui gydyti |
GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
CA3008171A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
KR101919189B1 (ko) * | 2016-02-18 | 2018-11-15 | 경북대학교 산학협력단 | 다중치환 4H-티아졸로[4,5-e][1,4]다이아제핀-5,8-다이온 유도체 및 이의 용도 |
AU2017321973B2 (en) | 2016-09-02 | 2024-09-05 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
CA3066939A1 (en) | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
SG11201912403SA (en) | 2017-06-22 | 2020-01-30 | Celgene Corp | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
US11649238B2 (en) * | 2018-01-17 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors |
CA3092779A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
CN108997372B (zh) * | 2018-07-31 | 2020-07-28 | 华中科技大学同济医学院附属协和医院 | 正电子显像用化合物、其中间体、制备方法和显像剂 |
AU2019340376A1 (en) | 2018-09-11 | 2021-04-08 | Curis Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
MX2021009142A (es) | 2019-02-06 | 2021-10-13 | Venthera Inc | Inhibidores topicos de fosfoinositol 3-cinasas. |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN112920199B (zh) * | 2020-06-02 | 2023-02-03 | 四川大学 | 一种哌嗪酮取代物或其衍生物及其制备方法和应用、药物组合物 |
CN113045582B (zh) * | 2021-02-05 | 2022-12-23 | 中国药科大学 | Parp-1/pi3k双靶点抑制剂或其药学上可接受的盐及其制备方法与用途 |
WO2023127883A1 (ja) | 2021-12-28 | 2023-07-06 | 日本新薬株式会社 | インダゾール化合物及び医薬 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
CH592668A5 (es) * | 1973-10-02 | 1977-10-31 | Delalande Sa | |
GB1570494A (en) | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
ZA782648B (en) | 1977-05-23 | 1979-06-27 | Ici Australia Ltd | The prevention,control or eradication of infestations of ixodid ticks |
CZ20001709A3 (cs) * | 1997-11-11 | 2001-12-12 | Pfizer Products Inc. | Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi |
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CN100345830C (zh) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
AU2003255845A1 (en) * | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
TWI498332B (zh) | 2006-04-26 | 2015-09-01 | Hoffmann La Roche | 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物 |
ES2347187T3 (es) * | 2006-04-26 | 2010-10-26 | F. Hoffmann-La Roche Ag | Derivado de tieno(3,2-d)pirimidina, util como un inhibidor de pi3k. |
US8247397B2 (en) * | 2007-09-12 | 2012-08-21 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
-
2004
- 2004-10-25 GB GBGB0423653.5A patent/GB0423653D0/en not_active Ceased
-
2005
- 2005-10-25 NZ NZ554585A patent/NZ554585A/en not_active IP Right Cessation
- 2005-10-25 ES ES05798278.7T patent/ES2554689T3/es active Active
- 2005-10-25 US US11/665,657 patent/US7776856B2/en not_active Expired - Fee Related
- 2005-10-25 CN CN2005800446399A patent/CN101087795B/zh not_active Expired - Fee Related
- 2005-10-25 MX MX2007004867A patent/MX2007004867A/es active IP Right Grant
- 2005-10-25 ES ES05797514.6T patent/ES2558867T3/es active Active
- 2005-10-25 EP EP05797514.6A patent/EP1812445B1/en not_active Not-in-force
- 2005-10-25 WO PCT/GB2005/004129 patent/WO2006046031A1/en active Application Filing
- 2005-10-25 BR BRPI0517461-9A patent/BRPI0517461A/pt not_active Application Discontinuation
- 2005-10-25 EP EP05798278.7A patent/EP1812446B1/en not_active Not-in-force
- 2005-10-25 CA CA2585089A patent/CA2585089C/en not_active Expired - Fee Related
- 2005-10-25 KR KR1020137013522A patent/KR101466529B1/ko not_active IP Right Cessation
- 2005-10-25 ES ES05796680.6T patent/ES2547447T3/es active Active
- 2005-10-25 CA CA2585112A patent/CA2585112C/en not_active Expired - Fee Related
- 2005-10-25 JP JP2007537400A patent/JP5048504B2/ja not_active Expired - Fee Related
- 2005-10-25 JP JP2007537399A patent/JP5078016B2/ja not_active Expired - Fee Related
- 2005-10-25 MX MX2007004868A patent/MX2007004868A/es active IP Right Grant
- 2005-10-25 JP JP2007537401A patent/JP5077946B2/ja not_active Expired - Fee Related
- 2005-10-25 CN CN2005800446384A patent/CN101087794B/zh not_active Expired - Fee Related
- 2005-10-25 EP EP05796680.6A patent/EP1812444B1/en not_active Not-in-force
- 2005-10-25 AU AU2005298408A patent/AU2005298408B2/en not_active Ceased
- 2005-10-25 BR BRPI0517019-2A patent/BRPI0517019A/pt active Search and Examination
- 2005-10-25 RU RU2007119373/04A patent/RU2422449C2/ru not_active IP Right Cessation
- 2005-10-25 RU RU2007119374/04A patent/RU2422448C2/ru not_active IP Right Cessation
- 2005-10-25 NZ NZ554586A patent/NZ554586A/en not_active IP Right Cessation
- 2005-10-25 WO PCT/GB2005/004146 patent/WO2006046040A1/en active Application Filing
- 2005-10-25 KR KR1020077011635A patent/KR20070084474A/ko not_active IP Right Cessation
- 2005-10-25 AU AU2005298404A patent/AU2005298404B2/en not_active Ceased
- 2005-10-25 KR KR1020077011637A patent/KR20070097422A/ko not_active Application Discontinuation
- 2005-10-25 WO PCT/GB2005/004137 patent/WO2006046035A1/en active Application Filing
-
2007
- 2007-04-17 IL IL182614A patent/IL182614A/en not_active IP Right Cessation
- 2007-04-17 IL IL182615A patent/IL182615A0/en unknown
- 2007-04-23 ZA ZA200703312A patent/ZA200703312B/xx unknown
- 2007-04-23 ZA ZA200703311A patent/ZA200703311B/en unknown
- 2007-04-24 NO NO20072116A patent/NO20072116L/no not_active Application Discontinuation
- 2007-04-24 NO NO20072115A patent/NO20072115L/no not_active Application Discontinuation
- 2007-08-16 US US11/893,625 patent/US7872003B2/en not_active Expired - Fee Related
- 2007-08-16 US US11/893,414 patent/US7750002B2/en not_active Expired - Fee Related
-
2010
- 2010-05-28 US US12/789,773 patent/US8153629B2/en not_active Expired - Fee Related
- 2010-07-13 US US12/835,533 patent/US8101607B2/en not_active Expired - Fee Related
-
2012
- 2012-03-08 US US13/415,672 patent/US20120258966A1/en not_active Abandoned
-
2013
- 2013-07-25 US US13/950,966 patent/US20130317017A1/en not_active Abandoned
-
2014
- 2014-06-17 US US14/307,364 patent/US8946217B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072115L (no) | Farmasoytiske forbindelser | |
RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
NO20084832L (no) | Pyrimidinderivater som P13K-inhibitorer | |
PE20071009A1 (es) | Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3 | |
NO20072833L (no) | Bi- og tricykliske substituterte fenylmetanoner som glycinetransportor I-(Glyt-1)-inhibitorer for behandling av Alzheimers sykdom | |
NO20065694L (no) | Indolderivat med piperidinring | |
PE20070833A1 (es) | Compuestos de pirimidinil benzotiofeno | |
HUP0203874A2 (hu) | Helyettesített 4-(fenil-N-alkil)piperazin és piperidinszármazékok és alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények | |
EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
RU2009136996A (ru) | Трициклические соединения, которые можно использовать для лечения нарушений, связанных с анормальным уровнем содержания железа в организме | |
PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
RU2007125658A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
TR200102789T2 (tr) | Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri | |
HUP0304101A2 (hu) | Pirazolszármazékok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények és intermedierjeik | |
RU98112237A (ru) | Новые производные индол-2,3-дион-3-оксима | |
UA66756C2 (uk) | Сполуки піперазину та піперидину, спосіб одержання сполук та спосіб лікування розладів центральної нервової системи | |
RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
CN110072862B (zh) | 二环性含氮杂环衍生物及含有该衍生物的药物组合物 | |
EA200400208A1 (ru) | Фенилацетамидотиазольные производные, способ их получения и их использования в качестве противоопухолевых средств | |
TW200420292A (en) | Benzofuran derivative | |
MXPA02011464A (es) | Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1. | |
DK0498718T3 (da) | Anvendelse af 4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridinderivater som indfangere af frie radikaler | |
RU2005100761A (ru) | Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов | |
NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |